We found little evidence to suggest that CypA or MMP9 affects the risk of Alzheimer’s disease or cognitive impairment using two-sample Mendelian randomization and polygenic risk score analysis in humans. Here, MMP9 is linked to early-onset autosomal dominant Alzheimer disease.